Therapeutic Potential of Curcumin for the Treatment of Brain Tumors

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Klinger, Neil V ^a   Mittal, Sandeep ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SIGNALING; CHEMOTHERAPY; DIAGNOSIS; MEDICAL APPLICATIONS; PLANTS (BOTANY); TOXICITY; TUMORS;

ADJUVANT CHEMOTHERAPY; ANTIPROLIFERATIVE PROPERTIES; G2/M CELL CYCLE ARREST; GLIOBLASTOMA MULTIFORME; MOLECULAR SIGNALING; NATURALLY OCCURRING; NUTRACEUTICAL COMPOUNDS; THERAPEUTIC POTENTIALS;

BRAIN;

ANTINEOPLASTIC AGENT; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; ANTIINFLAMMATORY AGENT; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BRAIN TUMOR; CANCER THERAPY; CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HUMAN; IC50; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINT; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PREVENTION AND CONTROL;

ANTI-INFLAMMATORY AGENTS; AUTOPHAGY; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS AS TOPIC; CURCUMIN; DRUG CARRIERS; HUMANS; NEOPLASM INVASIVENESS;

EID: 84994031878     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/9324085     Document Type: Review

References (104)

1. Q. T. Ostrom, H. Gittleman, P. Liao et al., "CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011, " Neuro-Oncology, vol. 16, supplement 4, pp. iv1-iv63, 2014.
2. S.-P. Weathers andM. R. Gilbert, "Advances in treating glioblastoma, " F1000Prime Reports, vol. 6, article 46, 2014.
3. R. Stupp, M. E. Hegi, W. P. Mason et al., "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, " The Lancet Oncology, vol. 10, no. 5, pp. 459-466, 2009.
4. R. Stupp, W. P. Mason, M. J. VanDen Bent et al., "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, " The New England Journal of Medicine, vol. 352, no. 10, pp. 987-996, 2005.
5. D. R. Johnson, H. E. Leeper, J. H. Uhm, "Glioblastoma survival in the United States improved after food and drug administration approval of bevacizumab: a population-based analysis, " Cancer, vol. 119, no. 19, pp. 3489-3495, 2013.
6. R. Stupp, S. Taillibert, A. A. Kanner et al., "Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial, " The Journal of the American Medical Association, vol. 314, no. 23, pp. 2535-2543, 2015.
7. B. B. Aggarwal, Y.-J. Surh, S. Shishodia, The Molecular Targets andTherapeutic Uses of Curcumin inHealth and Disease, Springer, 2007.
8. H. P. T. Ammon and M. A. Wahl, "Pharmacology of Curcuma longa, " Planta Medica, vol. 57, no. 1, pp. 1-7, 1991.
9. W.-H. Lee, C.-Y. Loo, M. Bebawy, F. Luk, R. S. Mason, R. Rohanizadeh, "Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century, " Current Neuropharmacology, vol. 11, no. 4, pp. 338-378, 2013.
10. A. Goel, A. B. Kunnumakkara, B. B. Aggarwal, "Curcumin as 'Curecumin': fromkitchen to clinic, " Biochemical Pharmacology, vol. 75, no. 4, pp. 787-809, 2008.
11. C. Schaaf, B. Shan, M. Buchfelder et al., "Curcumin acts as antitumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo, " Endocrine-Related Cancer, vol. 16, no. 4, pp. 1339-1350, 2009.
12. M. Miller, S. Chen, J. Woodliff, S. Kansra, "Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, decreases hormone levels and secretion in pituitary tumor cells, " Endocrinology, vol. 149, no. 8, pp. 4158-4167, 2008.
13. B. H. Choi, C. G. Kim, Y.-S. Bae, Y. Lim, Y. H. Lee, S. Y. Shin, "p21Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression, " Cancer Research, vol. 68, no. 5, pp. 1369-1377, 2008.
14. M. L. Y. Bangaru, S. Chen, J. Woodliff, S. Kansra, "Curcumin (diferuloylmethane) induces apoptosis and blocks migration of humanmedulloblastoma cells, " Anticancer Research, vol. 30, no. 2, pp. 499-504, 2010.
15. A. Zanotto-Filho, E. Braganhol, K. Klafke et al., "Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas, " Cancer Letters, vol. 358, no. 2, pp. 220-231, 2015.
16. W. Zhuang, L. Long, B. Zheng et al., "Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy, " Cancer Science, vol. 103, no. 4, pp. 684-690, 2012.
17. H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B. B. Aggarwal, Y. Kondo, "Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways, " Molecular Pharmacology, vol. 72, no. 1, pp. 29-39, 2007.
18. P. Langone, P. R. Debata, J. D. R. Inigo et al., "Coupling to a glioblastoma-directed antibody potentiates antitumor activity of curcumin, " International Journal of Cancer, vol. 135, no. 3, pp. 710-719, 2014.
19. S. Purkayastha, A. Berliner, S. S. Fernando et al., "Curcumin blocks brain tumor formation, " Brain Research, vol. 1266, pp. 130-138, 2009.
20. J. L. Arbiser, N. Klauber, R. Rohan et al., "Curcumin is an in vivo inhibitor of angiogenesis, " Molecular Medicine, vol. 4, no. 6, pp. 376-383, 1998.
21. S. Bisht, G. Feldmann, S. Soni et al., "Polymeric nanoparticleencapsulated curcumin ('nanocurcumin'): a novel strategy for human cancer therapy, " Journal of Nanobiotechnology, vol. 5, article 3, 18 pages, 2007.
22. M.-S. Woo, S.-H. Jung, S.-Y. Kim et al., "Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells, " Biochemical and Biophysical Research Communications, vol. 335, no. 4, pp. 1017-1025, 2005.
23. S.-Y. Kim, S.-H. Jung, H.-S. Kim, "Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells, " Biochemical and Biophysical Research Communications, vol. 337, no. 2, pp. 510-516, 2005.
24. S. S. Bhandarkar and J. L. Arbiser, "Curcumin as an inhibitor of angiogenesis, " in The Molecular Targets andTherapeutic Uses of Curcumin in Health and Disease, pp. 185-195, Springer, 2007.
25. D. Thaloor, A. K. Singh, G. S. Sidhu, P. V. Prasad, H. K. Kleinman, R. K. Maheshwari, "Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin, " Cell Growth and Differentiation, vol. 9, no. 4, pp. 305-312, 1998.
26. B. E. Bachmeier, A. G. Nerlich, C. M. Iancu et al., "The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice, " Cellular Physiology and Biochemistry, vol. 19, no. 1-4, pp. 137-152, 2007.
27. J. Ravindran, S. Prasad, B. B. Aggarwal, "Curcumin and cancer cells: how many ways can curry kill tumor cells selectively" The AAPS Journal, vol. 11, no. 3, pp. 495-510, 2009.
28. G. Sa and T. Das, "Anti cancer effects of curcumin: cycle of life and death, " Cell Division, vol. 3, no. 1, article 14, 2008.
29. N. Hasima and B. B. Aggarwal, "Cancer-linked targets modulated by curcumin, " International Journal of Biochemistry and Molecular Biology, vol. 3, no. 4, pp. 328-351, 2012.
30. P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara, B. B. Aggarwal, "Curcumin and cancer: an 'old-age' diseasewith an 'age-old' solution, " Cancer Letters, vol. 267, no. 1, pp. 133-164, 2008.
31. H. Hatcher, R. Planalp, J. Cho, F. M. Torti, S. V. Torti, "Curcumin: from ancient medicine to current clinical trials, " Cellular andMolecular Life Sciences, vol. 65, no. 11, pp. 1631-1652, 2008.
32. P. Rathore, P. Dohare, S. Varma et al., "Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain, " Neurochemical Research, vol. 33, no. 9, pp. 1672-1682, 2008.
33. J.-X. Wu, L.-Y. Zhang, Y.-L. Chen, S.-S. Yu, Y. Zhao, J. Zhao, "Curcumin pretreatment and post-treatment both improve the antioxidative ability of neurons with oxygen-glucose deprivation, " Neural Regeneration Research, vol. 10, no. 3, pp. 481-489, 2015.
34. T. Santel, G. Pflug, N. Y. A. Hemdan et al., "Curcumin inhibits glyoxalase 1-a possible link to its anti-inflammatory and antitumor activity, " PLoS ONE, vol. 3, no. 10, Article IDe3508, 2008.
35. B. Wu, H. Yao, S. Wang, R. Xu, "DAPK1 modulates a curcumin-induced G2/M arrest and apoptosis by regulating STAT3, NF-B, caspase-3 activation, " Biochemical and Biophysical Research Communications, vol. 434, no. 1, pp. 75-80, 2013.
36. E. Liu, J. Wu, W. Cao et al., "Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma, " Journal of Neuro-Oncology, vol. 85, no. 3, pp. 263-270, 2007.
37. I. Garkavtsev, S. V. Kozin, O. Chernova et al., "The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis, " Nature, vol. 428, no. 6980, pp. 328-332, 2004.
38. Y. Qian, J. Ma, X. Guo et al., "Curcumin enhances the radiosensitivity of U87 cells by inducingDUSP-2 up-regulation, " Cellular Physiology and Biochemistry, vol. 35, no. 4, pp. 1381-1393, 2015.
39. B. Pauwels, A. Wouters, M. Peeters, J. B. Vermorken, F. Lardon, "Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation, " Future Oncology, vol. 6, no. 9, pp. 1485-1496, 2010.
40. N. Aravindan, R. Madhusoodhanan, S. Ahmad, D. Johnson, T. S. Herman, "Curcumin inhibits NFB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells, " Cancer Biology and Therapy, vol. 7, no. 4, pp. 569-576, 2008.
41. A. K. Khaw, M. P. Hande, G. Kalthur, M. P. Hande, "Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells, " Journal of Cellular Biochemistry, vol. 114, no. 6, pp. 1257-1270, 2013.
42. T.-Y. Huang, T.-H. Tsai, C.-W. Hsu, Y.-C. Hsu, "Curcuminoids suppress the growth and induce apoptosis through caspase-3-dependent pathways in glioblastoma multiforme (GBM) 8401 cells, " Journal of Agricultural and Food Chemistry, vol. 58, no. 19, pp. 10639-10645, 2010.
43. S. Karmakar, N. L. Banik, S. K. Ray, "Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells, " Neurochemical Research, vol. 32, no. 12, pp. 2103-2113, 2007.
44. D. W. Davis, D. J. McConkey, J. L. Abbruzzese, R. S. Herbst, "Surrogate markers in antiangiogenesis clinical trials, " British Journal of Cancer, vol. 89, no. 1, pp. 8-14, 2003.
45. A. Zanotto-Filho, E. Braganhol, R. Schröder et al., "NFB inhibitors induce cell death in glioblastomas, " Biochemical Pharmacology, vol. 81, no. 3, pp. 412-424, 2011.
46. I. Bandey, S.-H. Chiou, A.-P. Huang, J.-C. Tsai, P.-H. Tu, "Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness, " Oncogene, vol. 34, no. 14, pp. 1853-1864, 2015.
47. K. M. Dhandapani, V. B. Mahesh, D. W. Brann, "Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFB transcription factors, " Journal of Neurochemistry, vol. 102, no. 2, pp. 522-538, 2007.
48. A. Belkaid, I. B. Copland, D. Massillon, B. Annabi, "Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin, " FEBS Letters, vol. 580, no. 15, pp. 3746-3752, 2006.
49. J. Weissenberger, M. Priester, C. Bernreuther et al., "Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1, 2/STAT3 signaling pathway, " Clinical Cancer Research, vol. 16, no. 23, pp. 5781-5795, 2010.
50. M. H. Elamin, Z. Shinwari, S.-F. Hendrayani et al., "Curcumin inhibits the sonic hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells, " Molecular Carcinogenesis, vol. 49, no. 3, pp. 302-314, 2010.
51. W.-Z. Du, Y. Feng, X.-F. Wang et al., "Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo, " CNS Neuroscience & Therapeutics, vol. 19, no. 12, pp. 926-936, 2013.
52. M. He, Y. Li, L. Zhang et al., "Curcumin suppresses cell proliferation through inhibition of the Wnt/-catenin signaling pathway in medulloblastoma, " Oncology Reports, vol. 32, no. 1, pp. 173-180, 2014.
53. S. J. Lee, C. Krauthauser, V. Maduskuie, P. T. Fawcett, J. M. Olson, S. A. Rajasekaran, "Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo, " BMC Cancer, vol. 11, article 114, 2011.
54. N. A. A. Thani, B. Sallis, R. Nuttall et al., "Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin, " Oncology Reports, vol. 28, no. 4, pp. 1435-1442, 2012.
55. K. Tsunoda, G. Kitange, T. Anda et al., "Expression of the constitutively activated RelA/NF-B in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, invasion, " Brain Tumor Pathology, vol. 22, no. 2, pp. 79-87, 2005.
56. B. Shan, C. Schaaf, A. Schmidt et al., "Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas, " Journal of Endocrinology, vol. 214, no. 3, pp. 389-398, 2012.
57. A. Zanotto-Filho, E. Braganhol, M. I. Edelweiss et al., "The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma, " The Journal of Nutritional Biochemistry, vol. 23, no. 6, pp. 591-601, 2012.
58. C. Ramachandran, S. M. Nair, E. Escalon, S. J. Melnick, "Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force-in brain tumor cell lines, " Journal of Complementary and Integrative Medicine, vol. 9, no. 1, article 20, 2012.
59. M. M. Hossain, N. L. Banik, S. K. Ray, "Synergistic anticancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells, " Neurochemistry International, vol. 61, no. 7, pp. 1102-1113, 2012.
60. S. Shukla, H. Zaher, A. Hartz, B. Bauer, J. A. Ware, S. V. Ambudkar, "Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice, " Pharmaceutical Research, vol. 26, no. 2, pp. 480-487, 2009.
61. I. Zhang, Y. Cui, A. Amiri, Y. Ding, R. E. Campbell, D. Maysinger, "Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 100, pp. 66-76, 2016.
62. P. M. Luthra, R. Kumar, A. Prakash, "Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells, " Biochemical and Biophysical Research Communications, vol. 384, no. 4, pp. 420-425, 2009.
63. T.-Y. Huang, C.-W. Hsu, W.-C. Chang, M.-Y. Wang, J.-F. Wu, Y.-C. Hsu, "Demethoxycurcumin retards cell growth and induces apoptosis in human brain malignant glioma GBM 8401 cells, " Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 396573, 11 pages, 2012.
64. C. A. Campos, J. B. Gianino, B. J. Bailey et al., "Design, synthesis, evaluation of curcumin-derived arylheptanoids for glioblastoma and neuroblastoma cytotoxicity, " Bioorganic andMedicinal Chemistry Letters, vol. 23, no. 24, pp. 6874-6878, 2013.
65. Y.-M. Tsai, C.-F. Chien, L.-C. Lin, T.-H. Tsai, "Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration, " International Journal of Pharmaceutics, vol. 416, no. 1, pp. 331-338, 2011.
66. B. S. Patil, G. K. Jayaprakasha, K. N. Chidambara Murthy, A. Vikram, "Bioactive compounds: historical perspectives, opportunities, challenges, " Journal of Agricultural and Food Chemistry, vol. 57, no. 18, pp. 8142-8160, 2009.
67. C. D. Lao, M. T. Ruffin, D. Normolle et al., "Dose escalation of a curcuminoid formulation, " BMC Complementary and Alternative Medicine, vol. 6, no. 1, article 10, 2006.
68. A.-L. Chen, C.-H. Hsu, J.-K. Lin et al., "Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, " Anticancer Research, vol. 21, no. 4, pp. 2895-2900, 2001.
69. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, P. S. S. R. Srinivas, "Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers, " PlantaMedica, vol. 64, no. 4, pp. 353-356, 1998.
70. C. K. Atal, R. K. Dubey, J. Singh, "Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism, " Journal of Pharmacology and ExperimentalTherapeutics, vol. 232, no. 1, pp. 258-262, 1985.
71. C. K. Atal, U. Zutshi, P. G. Rao, "Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs, " Journal of Ethnopharmacology, vol. 4, no. 2, pp. 229-232, 1981.
72. P. Anand, A. B. Kunnumakkara, R. A. Newman, B. B. Aggarwal, "Bioavailability of curcumin: problems and promises, " Molecular Pharmaceutics, vol. 4, no. 6, pp. 807-818, 2007.
73. R. S. Mulik, J. Mönkkönen, R. O. Juvonen, K. R. Mahadik, A. R. Paradkar, "ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells, " International Journal of Pharmaceutics, vol. 437, no. 1-2, pp. 29-41, 2012.
74. Y. Chen, L. Pan, M. Jiang, D. Li, L. Jin, "Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo, " Drug Delivery, vol. 23, no. 4, pp. 1383-1392, 2016.
75. M. T. Mirgani, B. Isacchi, M. Sadeghizadeh et al., "Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells, " International Journal of Nanomedicine, vol. 9, no. 1, pp. 403-417, 2014.
76. E. Babaei, M. Sadeghizadeh, Z. M. Hassan, M. A. H. Feizi, F. Najafi, S. M. Hashemi, "Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo, " International Immunopharmacology, vol. 12, no. 1, pp. 226-234, 2012.
77. V. Erfani-Moghadam, A. Nomani, M. Zamani, Y. Yazdani, F. Najafi, M. Sadeghizadeh, "A novel diblock copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles/polymersomes for curcumin delivery to cancer cells, " International Journal of Nanomedicine, vol. 9, no. 1, pp. 5541-5554, 2014.
78. X. Zhuang, X. Xiang, W. Grizzle et al., "Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain, " MolecularTherapy, vol. 19, no. 10, pp. 1769-1779, 2011.
79. R. G. Madane and H. S. Mahajan, "Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, in vivo study, " Drug Delivery, vol. 23, no. 4, pp. 1326-1334, 2016.
80. B. Farhangi, A. M. Alizadeh, H. Khodayari et al., "Protective effects of dendrosomal curcumin on an animal metastatic breast tumor, " European Journal of Pharmacology, vol. 758, pp. 188-196, 2015.
81. Z.-J. Sun, B. Sun, R.-B. Tao, X. Xie, X.-L. Lu, D.-L. Dong, "A poly(glycerol-sebacate-curcumin) polymer with potential use for brain gliomas, " Journal of BiomedicalMaterialsResearchPart A, vol. 101, no. 1, pp. 253-260, 2013.
82. G. Guo, S. Fu, L. Zhou et al., "Preparation of curcumin loaded poly(-caprolactone)-poly(ethylene glycol)-poly(-caprolactone) nanofibers and their in vitro antitumor activity against Glioma 9L cells, " Nanoscale, vol. 3, no. 9, pp. 3825-3832, 2011.
83. R. C. Gupta, S. S. Bansal, F. Aqil et al., "Controlled-release systemic delivery-a new concept in cancer chemoprevention, " Carcinogenesis, vol. 33, no. 8, pp. 1608-1615, 2012.
84. K. Shahani, S. K. Swaminathan, D. Freeman, A. Blum, L. Ma, J. Panyam, "Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention, " Cancer Research, vol. 70, no. 11, pp. 4443-4452, 2010.
85. S. Bisht, M. Mizuma, G. Feldmann et al., "Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer, " Molecular Cancer Therapeutics, vol. 9, no. 8, pp. 2255-2264, 2010.
86. K. J. Lim, S. Bisht, E. E. Bar, A. Maitra, C. G. Eberhart, "A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction inmalignant brain tumors, " Cancer Biology & Therapy, vol. 11, no. 5, pp. 464-473, 2011.
87. F. Dilnawaz and S. K. Sahoo, "Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, no. 3, pp. 452-462, 2013.
88. J.-H. Fang, Y.-H. Lai, T.-L. Chiu, Y.-Y. Chen, S.-H. Hu, S.-Y. Chen, "Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas, " Advanced HealthcareMaterials, vol. 3, no. 8, pp. 1250-1260, 2014.
89. P. Langone, P. R. Debata, S. Dolai et al., "Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin, " International Journal of Cancer, vol. 131, no. 4, pp. E569-E578, 2012.
90. E.-M. Strasser, B. Wessner, N. Manhart, E. Roth, "The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells, " Biochemical Pharmacology, vol. 70, no. 4, pp. 552-559, 2005.
91. M. Yoshino, M. Haneda, M. Naruse et al., "Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2-deoxyguanosine in DNA and induction of apoptotic cell death, " Toxicology in Vitro, vol. 18, no. 6, pp. 783-789, 2004.
92. K. Sakano and S. Kawanishi, "Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes, " Archives of Biochemistry and Biophysics, vol. 405, no. 2, pp. 223-230, 2002.
93. J. Nair, S. Strand, N. Frank et al., "Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper accumulation, " Carcinogenesis, vol. 26, no. 7, pp. 1307-1315, 2005.
94. N. Frank, J. Knauft, F. Amelung, J. Nair, H. Wesch, H. Bartsch, "No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases, " Mutation Research/Fundamental andMolecularMechanisms ofMutagenesis, vol. 523-524, pp. 127-135, 2003.
95. P. J. Moos, K. Edes, J. E. Mullally, F. A. Fitzpatrick, "Curcumin impairs tumor suppressor p53 function in colon cancer cells, " Carcinogenesis, vol. 25, no. 9, pp. 1611-1617, 2004.
96. S. Somasundaram, N. A. Edmund, D. T. Moore, G. W. Small, Y. Y. Shi, R. Z. Orlowski, "Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer, " Cancer Research, vol. 62, no. 13, pp. 3868-3875, 2002.
97. D. Fong, A. Yeh, R. Naftalovich, T. H. Choi, M. M. Chan, "Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals, " Cancer Letters, vol. 293, no. 1, pp. 65-72, 2010.
98. R. Galli, E. Binda, U. Orfanelli et al., "Isolation and characterization of tumorigenic, stem-like neural precursors fromhuman glioblastoma, " Cancer Research, vol. 64, no. 19, pp. 7011-7021, 2004.
99. M. Zhang, T. Song, L. Yang et al., "Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients, " Journal of Experimental & Clinical Cancer Research, vol. 27, no. 1, article 85, 1 page, 2008.
100. M. R. Gilbert, J. J. Dignam, T. S. Armstrong et al., "Arandomized trial of bevacizumab for newly diagnosed glioblastoma, " The New England Journal of Medicine, vol. 370, no. 8, pp. 699-708, 2014.
101. M. R. Gilbert, M. Wang, K. D. Aldape et al., "Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, " Journal of Clinical Oncology, vol. 31, no. 32, pp. 4085-4091, 2013.
102. O. L. Chinot, W. Wick, W. Mason et al., "Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma, " The New England Journal of Medicine, vol. 370, no. 8, pp. 709-722, 2014.
103. M. Westphal, O. Heese, J. P. Steinbach et al., "A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma, " European Journal of Cancer, vol. 51, no. 4, pp. 522-532, 2015.
104. R. Stupp, M. E. Hegi, T. Gorlia et al., "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, openlabel, phase 3 trial, "TheLancetOncology, vol. 15, no. 10, pp. 1100-1108, 2014.